|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Institute on Drug Abuse (NIDA) |
|---|---|
| Collaborator: |
VA Boston Healthcare System |
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00000309 |
Purpose
The purpose of this study is to evaluate use of risperidone with cocaine abusers. Study measures incorporate an appropriate integration of behavioral and neurobiological indices.
| Condition | Intervention | Phase |
|---|---|---|
|
Cocaine-Related Disorders |
Drug: Risperidone |
Phase II |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Serotonin/Dopamine Antagonism of Cocaine Effect |
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Please contact site for information.
Contacts and Locations| United States, Rhode Island | |
| Brown University School of Medicine | |
| Providence, Rhode Island, United States, 2906 | |
| Principal Investigator: | Lawrence Price, M.D. | Brown University |
More Information
| ClinicalTrials.gov Identifier: | NCT00000309 History of Changes |
| Other Study ID Numbers: | NIDA-09330-1, R01-09330-1 |
| Study First Received: | September 20, 1999 |
| Last Updated: | June 23, 2005 |
| Health Authority: | United States: Federal Government |
|
Cocaine-Related Disorders Substance-Related Disorders Mental Disorders Dopamine Risperidone Serotonin Cardiotonic Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Protective Agents Serotonin Receptor Agonists Serotonin Agents Serotonin Antagonists Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Central Nervous System Agents Psychotropic Drugs Dopamine Antagonists |